QST Consultations Selects Merge's eClinical OS(TM) Clinical Trial Platform

Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, today announced that QST Consultations, Ltd. has selected Merge's eClinical OS™ solution as its preferred clinical trial platform to support Phases I, II, and III and Post-Marketing studies on a global basis.

"We currently work with a range of sponsors that extend from small start-up organizations to well-established leaders in the pharmaceutical industry. We have developed significant therapeutic expertise in several key areas such as dermatology, ophthalmology, pulmonary, allergy, pain management, women's health, obesity, and several others that include wide-ranging support for dozens of approved submissions," explained Nancy Fitzgerald, CEO of QST Consultations. "Finding one system that is flexible enough to work for all types of studies was very important to us."

"We initially looked at eClinical OS because it is a single platform with all the study support capabilities we may need for a particular study, such as EDC, IWR/IVR, endpoint adjudication, or randomization," Fitzgerald continued. "Additionally, we were pleased with the option to choose self-service or partnering with Merge for study build services. With the intuitive study builder and built-in study templates, we can create studies quickly without having to outsource to a third party. This not only means we can improve timelines for our clients, but we can also better control costs, resulting in more competitive bids."

"With nearly 40 years experience providing clinical study consultation to the pharmaceutical and medical device industries, QST Consultations has used many different technologies to help clients manage and run studies," said Zaher El-Assi, President of Merge eClinical. "We're very pleased with their selection of Merge eClinical OS as a preferred solution and with their dedication in becoming a Merge certified expert-level builder. By implementing a single platform, they can spend less time and resources integrating numerous technologies for each study, and more time directly supporting the needs of their clients."

Merge eClinical OS has the flexibility to support trials in any stage, and captures any type of data, from any source, over any modality. Users benefit from the convenience of one operating platform with countless critical tools that can be mixed and matched to fit the needs of each trial environment.